TECH Signal 404
Moderna-Merck mRNA Vaccine Intismeran Plus Keytruda Meets Late-Stage Trial Goals in Melanoma
↗
Moderna and Merck's personalized mRNA cancer vaccine Intismeran, combined with Keytruda, reduced melanoma recurrence and spread in a late-stage trial, the first positive result for an mRNA cancer vaccine.
This validates mRNA technology as a cancer treatment platform, extending it beyond infectious disease vaccines into oncology. The success could accelerate similar mRNA cancer vaccine trials for other solid tumors currently underway by multiple companies, though results are years away.
Written by elseif from the cluster below · every claim links back to a sourceThe three things worth knowing
Intismeran met both its primary target of reducing cancer recurrence and its secondary goal of preventing tumor spread compared to Keytruda alone.
This is the first positive late-stage trial result for an mRNA cancer vaccine.
Merck and Moderna are in regulatory discussions, with potential approval as soon as next year for post-surgery high-risk melanoma patients.
THE CLUSTER